Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986707 | 0.97 | METAP2 (0.56) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3984405 | 0.88 | METAP2 (0.73) | METAP2GLO1MMP2 | |
| SCHEMBL3987166 | 0.86 | METAP2 (0.49) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3981280 | 0.83 | METAP2 (0.53) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3984043 | 0.83 | METAP2 (0.64) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3985681 | 0.80 | METAP2 (0.50) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3985674 | 0.80 | METAP2 (0.50) | METAP2TP53MAPTGLO1MMP2 | |
| SCHEMBL3979712 | 0.80 | TP53 (0.47) | TP53MAPT | |
| SCHEMBL3982577 | 0.79 | MAPT (0.60) | METAP2TP53MAPT | |
| SCHEMBL3983467 | 0.79 | TSHR (0.52) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885TP53 1079/4885MAPT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.